Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of JW0105 vs Co-administration of JW0104 and C2402 in Healthy Volunteers
NCT06754943Phase 1Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Jan 2025
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pitavastatin, amlodipine and valsartan in hypertension (HTN) and dyslipidemia (2 arms), sponsored by JW Pharmaceutical Corporation. Primary endpoints: Area Under the Concentration-time Curve from Time Zero to Time t at Day 3 and Maximum Plasma Concentration at Day 3. Started Jan 2025; status: completed.
02
Drugs
pitavastatinamlodipinevalsartan
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT06754943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06754943.